Trial Profile
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Jul 2007
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 29 Oct 2005 New trial record.